A5028444678- Extracellular vesicles in disease
- Dialysis and Renal Disease Management
- Genetic and Kidney Cyst Diseases
- Pregnancy and preeclampsia studies
- Magnesium in Health and Disease
- Biomedical Research and Pathophysiology
- Inflammatory Biomarkers in Disease Prognosis
- Renal Diseases and Glomerulopathies
- Ion Transport and Channel Regulation
- Pancreatic and Hepatic Oncology Research
- Neuroendocrine Tumor Research Advances
- Viral Infections and Vectors
- Renal and Vascular Pathologies
- Urologic and reproductive health conditions
- Diabetes Treatment and Management
- Liver Disease Diagnosis and Treatment
- Renal function and acid-base balance
- Urinary Bladder and Prostate Research
Erasmus MC
2018-2024
Erasmus University Rotterdam
2021
Abstract Urine is commonly used for clinical diagnosis and biomedical research. The discovery of extracellular vesicles (EV) in urine opened a new fast‐growing scientific field. In the last decade urinary (uEVs) were shown to mirror molecular processes as well physiological pathological conditions kidney, urothelial prostate tissue. Therefore, several methods isolate characterize uEVs have been developed. However, methodological aspects EV separation analysis, including normalization...
<h3>Importance</h3> Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive cyst formation in both kidneys and loss of renal function, eventually leading to a need for replacement therapy. There are limited therapeutic management options. <h3>Objective</h3> To examine the effect somatostatin analogue lanreotide on rate function patients with later-stage ADPKD. <h3>Design, Setting, Participants</h3> An open-label randomized clinical trial blinded end point...
Significance Statement Urinary extracellular vesicles (uEVs) are a promising noninvasive source of kidney biomarkers, but the optimal approaches for normalization, quantification, and characterization in spot urines unclear. To address hypothesis that urine creatinine can be used as normalization variable, particles were quantified dilute concentrated (water deprivation–loading study) randomly from healthy subjects patients with disease. In these various settings, was highly correlated...
Abstract Urinary extracellular vesicles (uEVs) are emerging as non‐invasive biomarkers for various kidney diseases, but it is unknown how differences in nephron mass impact uEV excretion. To address this, excretion was measured before and after human donor nephrectomy rat nephrectomy. In male female donors, uEVs were quantified cell‐free spot 24‐h urine samples using nanoparticle tracking analysis (NTA), EVQuant, CD9‐time‐resolved fluorescence immunoassay. Female donors had significantly...
Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are well-established glucose-lowering drugs for type 2 diabetes mellitus (T2DM) management. Acute GLP-1RA administration increases urinary excretion of sodium and other electrolytes. However, the renal tubular effects prolonged treatment largely unknown. In this secondary analysis a randomized trial, we determined 8-wk with 20 μg lixisenatide, short-acting (prandial) GLP-1RA, versus titrated once-daily insulin glulisine in 35 overweight...
Significance Statement There is an unmet need for biomarkers of disease progression in autosomal dominant polycystic kidney (ADPKD). This study investigated urinary extracellular vesicles (uEVs) as a source such biomarkers. Proteomic analysis uEVs identified matrix metalloproteinase 7 (MMP-7) biomarker predictive rapid progression. In validation studies, MMP-7 was but not whole urine, possibly because are primarily secreted by tubular epithelial cells. Indeed, single-nucleus RNA sequencing...
"Urine can provide us day by day, month month, and year with a serial story of the major events within kidney." Dr. Thomas Addis, pioneer in renal physiology, came to this conclusion 1948. The discovery urinary extracellular vesicles (uEVs) as molecular mimics kidney
Abstract Background Metabolic acidosis accelerates progression of chronic kidney disease, but whether this is also true for autosomal dominant polycystic disease (ADPKD) unknown. Methods Patients with ADPKD from the DIPAK (Developing Interventions to halt Progression ADPKD) trial were included [n = 296, estimated glomerular filtration rate (eGFR) 50 ± 11 mL/min/1.73 m2, 2.5 years follow-up]. Outcomes worsening function (30% decrease in eGFR or failure), annual change and height-adjusted...
Gallstones are a known adverse effect of somatostatin analogs, but the exact incidence and clinical implications unknown.The aim this study was to investigate gallstones on imaging related complications in unbiased trial data.Data from DIPAK 1 trial, which 305 polycystic kidney disease patients were randomized standard care (SoC) or lanreotide for 120 weeks, used. Magnetic resonance (MRI) performed at baseline end treatment assessed presence, number, size gallstones. For all who had we...
Background: Epidermal growth factor is expressed in the distal tubule and secreted urine (uEGF) after cleavage of membrane-bound pro-EGF. Lower uEGF associated with kidney disease progression. EGF also plays a role regulation serum magnesium blood pressure, but whether these parameters unknown. We hypothesized that marker magnesium, outcomes. Methods: first used cohort donors (n = 20) measured to analyze association tubular mass pro-EGF urinary extracellular vesicles as proxy for expression....
Extracellular vesicles (EVs) are evolving as novel cell mediators, biomarkers, and therapeutic targets in kidney health disease. They naturally derived from cells both within outside the carry cargo which mirrors state of parent cell. Thus, they potentially more sensitive disease-specific biomarkers messengers various diseases. Beside their role communicators nephron, likely communicate between different organs affected by Study urinary EVs (uEVs) can help to fill current knowledge gaps...